| Literature DB >> 27911870 |
Zhihua Yin1,2, Zhigang Cui3, Yangwu Ren1,2, Lingzi Xia1,2, Hang Li1,2, Baosen Zhou1,2.
Abstract
This study provides evidence that the common rs2910164 polymorphism in miR-146a strongly correlates with lung cancer risk in nonsmoking females in northeast China. The genotypes of miR-146a rs2910164 were determined in 1131 patients with lung cancer and 1003 healthy control subjects. Tissue samples were used to evaluate the association between miRNA expression and lung cancer risk as well as the correlation between rs2910164 genotypes and miR-146a expression. The secondary structures of the wild-type and variant miR-146a sequences were predicted, and luciferase-based target assays were used to test whether miR-146a bound to tumor necrosis factor receptor associated factor 6 (TRAF6) mRNA. Individuals carrying heterozygous CG genotype of miR-146a rs2910164 had less risk of lung cancer than those carrying homozygous wild CC genotype (OR = 0.76, 95% CI = 0.60-0.98, P = 0.032). We found no significant association between miR-146a expression and lung cancer risk. MiR-146a expression differed in those carrying the CC genotype as compared with the CG or the GG genotype (P = 0.032 and 0.001), and the secondary structure of the C allele differed slightly from the G allele. Significantly lower levels of luciferase activity were observed when the TRAF6 3'UTR was cotransfected with miR-146a-3p carrying the rs2910164 C allele (P = 0.001). Thus, miR-146a rs2910164 polymorphism may influence susceptibility to lung cancer in Chinese nonsmoking females through targeting TRAF6.Entities:
Keywords: gene expression; genetic susceptibility; lung cancer; microRNA; single nucleotide polymorphism
Mesh:
Substances:
Year: 2017 PMID: 27911870 PMCID: PMC5356798 DOI: 10.18632/oncotarget.13722
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Allele and genotype frequencies of miR-146a polymorphism among cases and control subjects in nonsmoking female population
| SNP | First stage | Second stage | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases (%) | Control subjects (%) | OR (95%C1) | Cases (%) | Control subjects (%) | OR (95%CI) | |||
| CC (ref) | 198 (34.4) | 168 (27.6) | 1.00 (ref) | 179 (32.2) | 122 (30.9) | 1.00 (ref) | ||
| CG | 280 (48.7) | 313 (51.5) | 0.76 (0.59-0.99) | 0.039 | 270 (48.6) | 195 (49.4) | 0.94(0.70-1.27) | 0.700 |
| GG | 97(16.9) | 127 (20.9) | 0.65 (0.46-0.91) | 0.011 | 107(19.2) | 78(19.7) | 0.94 (0.65-1.36) | 0.723 |
| Dominant model | 0.73 (0.57-0.93) | 0.012 | 0.94 (0.71-1.24) | 0.669 | ||||
| CG+GG vs | ||||||||
| CC | ||||||||
| Recessive | 0.77 (0.57-1.03) | 0.078 | 0.97 (0.70-1.34) | 0.847 | ||||
| model GG | ||||||||
| vs CC+CG | ||||||||
| C allele (ref) | 676 (58.8) | 649 (53.4) | 1.00 (ref) | — | 628 (56.5) | 439 (55.6) | 1.00 (ref) | — |
| G allele | 474 (41.2) | 567 (46.6) | 0.80 (0.68-0.94) | 0.008 | 484 (43.5) | 351 (44.4) | 0.96 (0.80-1.16) | 0.695 |
The association of miR-146a polymorphism and lung cancer risk
| SNP | Cases(%) | Control subjects (%) | OR (95%CI) | OR (95%CI)* | ||
|---|---|---|---|---|---|---|
| CC(ref) | 377 (33.3) | 290 (28.9) | 1.00 (ref) | 1.00 (ref) | ||
| CG | 550 (48.6) | 508 (50.6) | 0.83 (0.69-1.01) | 0.066 | 0.83 (0.69-1.01) | 0.068 |
| GG | 204(18.0) | 205 (20.4) | 0.77 (0.60-0.98) | 0.034 | 0.76 (0.60-0.98) | 0.032 |
| Dominant model CG+GG vs CC | 0.81 (0.68-0.98) | 0.028 | 0.81 (0.68-0.98) | 0.028 | ||
| Recessive model GG vs CC+CG | 0.86(0.69-1.06) | 0.160 | 0.85 (0.69-1.06) | 0.148 | ||
| C allele (ref) | 1304 (57.6) | 1088 (54.2) | 1.00 (ref) | — | ||
| G allele | 958 (42.4) | 918 (45.8) | 0.87 (0.77-0.98) | 0.025 |
Abbreviation: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. *ORs were calculated by unconditional logistic regression and adjusted for age.
The association of miR-146a polymorphism and lung cancer risk by cancer type
| SNP | OR (95%CI) | OR (95%CI)* | ||
|---|---|---|---|---|
| CC(ref) | 1.00 (ref) | 1.00 (ref) | ||
| CG | 0.82 (0.66-1.01) | 0.061 | 0.82 (0.66-1.01) | 0.063 |
| GG | 0.71 (0.54-0.93) | 0.014 | 0.71 (0.54-0.93) | 0.013 |
| Dominant model | 0.78 (0.64-0.96) | 0.018 | 0.78 (0.64-0.96) | 0.019 |
| CG+GG vs CC | ||||
| Recessive model GG | 0.80 (0.63-1.02) | 0.075 | 0.80 (0.63-1.02) | 0.070 |
| vs CC+CG | ||||
| C allele(ref) | 1.00 (ref) | |||
| G allele | 0.84 (0.73-0.96) | 0.011 | ||
| CC(ref) | 1.00 (ref) | 1.00 (ref) | ||
| CG | 0.83 (0.59-1.18) | 0.295 | 0.84 (0.59-1.19) | 0.328 |
| GG | 0.88 (0.57-1.36) | 0.578 | 0.89 (0.57-1.37) | 0.582 |
| Dominant model | 0.85 (0.61-1.17) | 0.315 | 0.85 (0.61-1.19) | 0.342 |
| CG+GG vs CC | ||||
| Recessive model GG | 0.99 (0.68-1.45) | 0.966 | 0.99 (0.67-1.44) | 0.939 |
| vs CC+CG | ||||
| C allele(ref) | 1.00 (ref) | — | ||
| G allele | 0.93 (0.75-1.15) | 0.499 |
Abbreviation: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. *ORs were calculated by unconditional logistic regression and adjusted for age.
Figure 1Sequence variations in the miR-146a can influence its expression
The relative expression (2-△△Ct) of miR-146a to U6 was significantly different between the CC genotype and the CG or GG genotype.
Figure 2Sequence variations in the miR-146a can translate into structural alterations
The RNA secondary structure was predicted by RNAHYbrid. Only the most stable secondary structures with the lowest free energy are depicted.
Figure 3In vitro target binding assays for rs2910164 in A549 cell lines
Each transfection was performed with pRL-SV40 plasmids as normalizing controls. Data presented are the mean fold increase ± SD from 3 independent transfection experiments, and each was done in triplicate.